Trial reportEuropean journal of nuclear medicine and molecular imaging2008
Selective hepatic arterial infusion of In-111-DTPA-Phe1-octreotide in neuroendocrine liver metastases.
Trial report in European journal of nuclear medicine and molecular imaging, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 68 citations in OpenAlex.
- Contemporary opportunities and potential of Auger electron-emitting theranostics.Theranostics · 2026Review
- Radioligand therapies in meningioma: Evidence and future directions.Neuro-oncology · 2024Review
- Review
- Review
- Article
- Auger electrons for cancer therapy - a review.EJNMMI radiopharmacy and chemistry · 2019Review
- Antitumor Activity of Auger Electron EmitterFrontiers in pharmacology · 2018Article
- Theranostics of Neuroendocrine Tumors.Visceral medicine · 2017Review
- Targeted Therapy for Medullary Thyroid Cancer: A Review.Frontiers in oncology · 2017Review
- Peptide receptor radionuclide therapy: focus on bronchial neuroendocrine tumors.Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine · 2016Review
- Localized Irradiation of Cell Membrane by Auger Electrons Is Cytotoxic Through Oxidative Stress-Mediated Nontargeted Effects.Antioxidants & redox signaling · 2016Article
- Merkel Cell Carcinoma Therapeutic Update.Current treatment options in oncology · 2016Review
- Peptide receptor radionuclide therapy using radiolabeled somatostatin analogs: focus on future developments.Clinical and translational imaging · 2014Review
- Intra-arterial liver-directed therapies for neuroendocrine hepatic metastases.Seminars in interventional radiology · 2013Review
- Lutetium-labelled peptides for therapy of neuroendocrine tumours.European journal of nuclear medicine and molecular imaging · 2012Review
- ¹¹¹In-DTPA⁰-octreotide (Octreoscan), ¹³¹I-MIBG and other agents for radionuclide therapy of NETs.European journal of nuclear medicine and molecular imaging · 2012Review
- Neuroendocrine tumors: a focus on liver metastatic lesions.Frontiers in oncology · 2012Article
- Diagnosis and therapy are walking together on radiopeptides' avenue.European journal of nuclear medicine and molecular imaging · 2011Article
- Multimodal management of neuroendocrine liver metastases.HPB : the official journal of the International Hepato Pancreato Biliary Association · 2010Review
- Auger: The future of precision medicine.Nuclear medicine and biologyReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeThe aim of this study is to evaluate the effectiveness of (111)In-DTPA-Phe(1)-octreotide infusions after selective catheterization of the hepatic artery in inoperable metastasised liver, sst(2) receptor-positive neuroendocrine tumours due to the effect of (111)In Auger electron emission, minimising in parallel the toxicity of non-target tissue.
methodsThe average dose per session administered monthly to each patient (17 cases in total) was 6.3+/-2.3 GBq. Repetitions did not exceed 12-fold, except in one case (15 sessions). Response assessment was classified according to the Response Evaluating Criteria in Solid Tumours. CT/MRI scans were performed as baseline before, during and after the end of treatment, and monthly ultrasound images for follow-up measurements. Toxicity (World Health Organization criteria) was measured using blood and urine tests of renal, hepatic and bone marrow function.
resultsComplete response was achieved in one (5.9%) patient and partial in eight (47.0%), and disease stabilization in 3 (17.7%) patients; five (29.4%) did not respond. A 32-month median survival time was estimated in 12 (70.5%). Nine of these 12 surviving had a mean target diameter shrinkage from 144+/-81 to 60+/-59 mm. Grade 1 erythro-, leuko- and thrombo-cytopenia occurred in three (17.6%) cases.
conclusionIn unresectable metastatic liver lesions positive for somatostatin receptors repeated, transhepatic high doses of (111)In-DTPA-Phe(1)-octreotide show an effective therapeutic outcome. Given the locoregional modality character of the administration technique plus the extremely short range of (111)In Auger and internal conversion electrons emission, no nephro-, liver- or myelo-toxicity has so far been observed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.